<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p47" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_47{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_47{left:341px;bottom:30px;}
#t3_47{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_47{left:377px;bottom:30px;}
#t5_47{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_47{left:540px;bottom:30px;}
#t7_47{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_47{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_47{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_47{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_47{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_47{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_47{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_47{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_47{left:1109px;bottom:47px;letter-spacing:0.18px;}
#tg_47{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_47{left:36px;bottom:293px;}
#ti_47{left:46px;bottom:287px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_47{left:377px;bottom:287px;letter-spacing:0.12px;}
#tk_47{left:45px;bottom:273px;letter-spacing:0.13px;}
#tl_47{left:119px;bottom:273px;}
#tm_47{left:36px;bottom:266px;}
#tn_47{left:46px;bottom:260px;letter-spacing:0.09px;word-spacing:-0.03px;}
#to_47{left:45px;bottom:246px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tp_47{left:45px;bottom:232px;letter-spacing:0.08px;word-spacing:0.06px;}
#tq_47{left:36px;bottom:224px;}
#tr_47{left:46px;bottom:218px;letter-spacing:0.1px;word-spacing:0.02px;}
#ts_47{left:45px;bottom:205px;letter-spacing:0.11px;}
#tt_47{left:45px;bottom:191px;letter-spacing:0.1px;word-spacing:-0.07px;}
#tu_47{left:45px;bottom:177px;letter-spacing:0.13px;}
#tv_47{left:36px;bottom:169px;}
#tw_47{left:46px;bottom:163px;letter-spacing:0.12px;word-spacing:0.02px;}
#tx_47{left:45px;bottom:150px;letter-spacing:0.12px;word-spacing:0.01px;}
#ty_47{left:45px;bottom:136px;letter-spacing:0.12px;}
#tz_47{left:36px;bottom:128px;}
#t10_47{left:46px;bottom:122px;letter-spacing:0.13px;word-spacing:-0.05px;}
#t11_47{left:45px;bottom:108px;letter-spacing:0.08px;word-spacing:0.06px;}
#t12_47{left:171px;bottom:108px;}
#t13_47{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t14_47{left:765px;bottom:786px;}
#t15_47{left:36px;bottom:757px;letter-spacing:-0.1px;}
#t16_47{left:36px;bottom:740px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t17_47{left:36px;bottom:723px;letter-spacing:-0.09px;word-spacing:0.01px;}
#t18_47{left:36px;bottom:706px;letter-spacing:-0.08px;}
#t19_47{left:41px;bottom:690px;}
#t1a_47{left:58px;bottom:690px;letter-spacing:-0.09px;}
#t1b_47{left:58px;bottom:673px;letter-spacing:-0.1px;}
#t1c_47{left:41px;bottom:656px;}
#t1d_47{left:58px;bottom:656px;letter-spacing:-0.09px;}
#t1e_47{left:459px;bottom:663px;}
#t1f_47{left:36px;bottom:639px;letter-spacing:-0.09px;}
#t1g_47{left:36px;bottom:622px;}
#t1h_47{left:47px;bottom:622px;letter-spacing:-0.1px;}
#t1i_47{left:41px;bottom:605px;}
#t1j_47{left:58px;bottom:605px;letter-spacing:-0.13px;}
#t1k_47{left:63px;bottom:589px;}
#t1l_47{left:76px;bottom:589px;letter-spacing:-0.09px;}
#t1m_47{left:77px;bottom:572px;letter-spacing:-0.09px;}
#t1n_47{left:77px;bottom:555px;letter-spacing:-0.09px;}
#t1o_47{left:77px;bottom:538px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1p_47{left:91px;bottom:521px;letter-spacing:-0.1px;}
#t1q_47{left:365px;bottom:529px;}
#t1r_47{left:77px;bottom:505px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t1s_47{left:92px;bottom:486px;letter-spacing:-0.09px;word-spacing:0.01px;}
#t1t_47{left:103px;bottom:468px;letter-spacing:-0.09px;}
#t1u_47{left:92px;bottom:450px;}
#t1v_47{left:103px;bottom:450px;letter-spacing:-0.09px;}
#t1w_47{left:77px;bottom:433px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1x_47{left:91px;bottom:416px;letter-spacing:-0.09px;}
#t1y_47{left:63px;bottom:399px;}
#t1z_47{left:76px;bottom:399px;letter-spacing:-0.09px;}
#t20_47{left:77px;bottom:382px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t21_47{left:562px;bottom:390px;}
#t22_47{left:36px;bottom:349px;letter-spacing:-0.1px;}
#t23_47{left:614px;bottom:757px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t24_47{left:956px;bottom:764px;letter-spacing:-0.12px;}
#t25_47{left:614px;bottom:740px;letter-spacing:-0.1px;}
#t26_47{left:620px;bottom:723px;}
#t27_47{left:636px;bottom:723px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t28_47{left:620px;bottom:706px;}
#t29_47{left:636px;bottom:706px;letter-spacing:-0.09px;}
#t2a_47{left:636px;bottom:690px;letter-spacing:-0.09px;}
#t2b_47{left:797px;bottom:697px;}
#t2c_47{left:496px;bottom:329px;}
#t2d_47{left:506px;bottom:323px;letter-spacing:-0.03px;word-spacing:0.01px;}
#t2e_47{left:505px;bottom:309px;letter-spacing:-0.04px;}
#t2f_47{left:505px;bottom:296px;letter-spacing:-0.02px;}
#t2g_47{left:728px;bottom:304px;}
#t2h_47{left:733px;bottom:296px;letter-spacing:-0.03px;}
#t2i_47{left:505px;bottom:282px;letter-spacing:-0.03px;word-spacing:0.01px;}
#t2j_47{left:505px;bottom:268px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t2k_47{left:505px;bottom:254px;letter-spacing:-0.03px;}
#t2l_47{left:505px;bottom:241px;letter-spacing:-0.06px;word-spacing:0.03px;}
#t2m_47{left:505px;bottom:227px;letter-spacing:-0.03px;}
#t2n_47{left:505px;bottom:213px;letter-spacing:-0.03px;}
#t2o_47{left:505px;bottom:199px;letter-spacing:-0.06px;word-spacing:0.03px;}
#t2p_47{left:505px;bottom:186px;letter-spacing:-0.04px;}
#t2q_47{left:505px;bottom:172px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t2r_47{left:505px;bottom:158px;letter-spacing:-0.04px;}
#t2s_47{left:505px;bottom:144px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t2t_47{left:505px;bottom:131px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t2u_47{left:505px;bottom:117px;letter-spacing:-0.03px;}
#t2v_47{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_47{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_47{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_47{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_47{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_47{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_47{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_47{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_47{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_47{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_47{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_47{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_47{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_47{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_47{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_47{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts47" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg47Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg47" style="-webkit-user-select: none;"><object width="1210" height="935" data="47/47.svg" type="image/svg+xml" id="pdf47" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_47" class="t s0_47">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_47" class="t s1_47">® </span>
<span id="t3_47" class="t s0_47">(NCCN </span>
<span id="t4_47" class="t s1_47">® </span>
<span id="t5_47" class="t s0_47">), All rights reserved. NCCN Guidelines </span>
<span id="t6_47" class="t s1_47">® </span>
<span id="t7_47" class="t s0_47">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_47" class="t s2_47">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_47" class="t s2_47">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_47" class="t s3_47">NCCN Guidelines Version 4.2024 </span>
<span id="tb_47" class="t s3_47">Cancer of the Glottic Larynx </span>
<span id="tc_47" class="t s4_47">NCCN Guidelines Index </span>
<span id="td_47" class="t s4_47">Table of Contents </span>
<span id="te_47" class="t s4_47">Discussion </span>
<span id="tf_47" class="t s5_47">GLOT-A </span>
<span id="tg_47" class="t s5_47">1 OF 2 </span>
<span id="th_47" class="t s6_47">1 </span>
<span id="ti_47" class="t s7_47">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_47" class="t s8_47">and </span>
<span id="tk_47" class="t s7_47">Discussion</span><span id="tl_47" class="t s8_47">. </span>
<span id="tm_47" class="t s6_47">2 </span>
<span id="tn_47" class="t s8_47">Gowda RV, Henk JM, Mais KL, et al. Three weeks radiotherapy </span>
<span id="to_47" class="t s8_47">for T1 glottic cancer: the Christie and Royal Marsden Hospital </span>
<span id="tp_47" class="t s8_47">Experience. Radiother Oncol 2003;68:105-111. </span>
<span id="tq_47" class="t s6_47">3 </span>
<span id="tr_47" class="t s8_47">For doses &gt;70 Gy, some clinicians feel that the fractionation </span>
<span id="ts_47" class="t s8_47">should be slightly modified (eg, &lt;2.0 Gy/fraction for at least </span>
<span id="tt_47" class="t s9_47">some of the treatment) to minimize toxicity. An additional 2–3 </span>
<span id="tu_47" class="t s8_47">doses can be added depending on clinical circumstances. </span>
<span id="tv_47" class="t s6_47">4 </span>
<span id="tw_47" class="t s8_47">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT </span>
<span id="tx_47" class="t s8_47">or 54–63 Gy with IMRT dose painting technique (dependent on </span>
<span id="ty_47" class="t s8_47">dose per fraction). </span>
<span id="tz_47" class="t s6_47">5 </span>
<span id="t10_47" class="t s7_47">Principles of Systemic Therapy for Non-Nasopharyngeal </span>
<span id="t11_47" class="t s7_47">Cancers (SYST-A)</span><span id="t12_47" class="t s8_47">. </span>
<span id="t13_47" class="t s5_47">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t14_47" class="t sa_47">1 </span>
<span id="t15_47" class="t s5_47">DEFINITIVE: </span>
<span id="t16_47" class="t s5_47">RT Alone </span>
<span id="t17_47" class="t s5_47">• Tis,N0: 60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) </span>
<span id="t18_47" class="t s5_47">• T1,N0: </span>
<span id="t19_47" class="t sb_47"></span><span id="t1a_47" class="t s5_47">63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) </span>
<span id="t1b_47" class="t s5_47">or </span>
<span id="t1c_47" class="t sb_47"></span><span id="t1d_47" class="t s5_47">50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction) </span>
<span id="t1e_47" class="t sa_47">2 </span>
<span id="t1f_47" class="t s5_47">• T2,N0: 65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction) </span>
<span id="t1g_47" class="t s5_47">• </span><span id="t1h_47" class="t sc_47">≥T2,N1: </span>
<span id="t1i_47" class="t sb_47"></span><span id="t1j_47" class="t s5_47">PTV </span>
<span id="t1k_47" class="t sd_47">◊ </span><span id="t1l_47" class="t s5_47">High risk: Primary tumor and involved lymph nodes [this </span>
<span id="t1m_47" class="t sc_47" data-mappings='[[38,"fi"]]'>includes possible local subclinical inﬁltration at the primary site </span>
<span id="t1n_47" class="t s5_47">and at the high-risk level lymph node(s)] </span>
<span id="t1o_47" class="t s5_47">– Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); </span>
<span id="t1p_47" class="t s5_47">daily Monday–Friday in 6–7 weeks </span>
<span id="t1q_47" class="t sa_47">3 </span>
<span id="t1r_47" class="t s5_47">– Concomitant boost accelerated RT: </span>
<span id="t1s_47" class="t sc_47" data-mappings='[[40,"fi"]]'>▪ 72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as </span>
<span id="t1t_47" class="t s5_47">second daily fraction during last 12 treatment days) </span>
<span id="t1u_47" class="t sc_47">▪ </span><span id="t1v_47" class="t s5_47">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1w_47" class="t s5_47">– Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction, </span>
<span id="t1x_47" class="t s5_47">twice daily) </span>
<span id="t1y_47" class="t sd_47">◊ </span><span id="t1z_47" class="t s5_47">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t20_47" class="t s5_47">– 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t21_47" class="t sa_47">4 </span>
<span id="t22_47" class="t s5_47">Either IMRT (preferred) or 3D-CRT is recommended. </span>
<span id="t23_47" class="t s5_47">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t24_47" class="t sa_47">5,6 </span>
<span id="t25_47" class="t s5_47">• PTV </span>
<span id="t26_47" class="t sb_47"></span><span id="t27_47" class="t s5_47">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t28_47" class="t sb_47"></span><span id="t29_47" class="t s5_47">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy </span>
<span id="t2a_47" class="t s5_47">(1.6–1.8 Gy/fraction) </span>
<span id="t2b_47" class="t sa_47">4 </span>
<span id="t2c_47" class="t s6_47">6 </span>
<span id="t2d_47" class="t s8_47">Based on published data, concurrent systemic therapy/RT most commonly uses conventional </span>
<span id="t2e_47" class="t s8_47">fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin </span>
<span id="t2f_47" class="t s8_47">given every 3 weeks at 100 mg/m </span>
<span id="t2g_47" class="t s0_47">2 </span>
<span id="t2h_47" class="t s8_47">; 2–3 cycles of chemotherapy are used depending on the radiation </span>
<span id="t2i_47" class="t s8_47">fractionation scheme (RTOG 0129) (Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and </span>
<span id="t2j_47" class="t s8_47">survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35). When carboplatin </span>
<span id="t2k_47" class="t s8_47">and 5-FU are used, then the recommended regimen is standard fractionation plus 3 cycles of </span>
<span id="t2l_47" class="t s8_47">chemotherapy [Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration </span>
<span id="t2m_47" class="t s8_47">of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck </span>
<span id="t2n_47" class="t s8_47">carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145- </span>
<span id="t2o_47" class="t s9_47">153]. Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing </span>
<span id="t2p_47" class="t s8_47">schedules of cisplatin, or altered fractionation with chemotherapy are efficacious, and there is no </span>
<span id="t2q_47" class="t s8_47">consensus on the optimal approach. In general, the use of concurrent systemic therapy/RT carries </span>
<span id="t2r_47" class="t s8_47">a high toxicity burden; multiagent chemotherapy will likely further increase the toxicity burden. For </span>
<span id="t2s_47" class="t s8_47">any systemic therapy/RT approach, close attention should be paid to published reports for the </span>
<span id="t2t_47" class="t s8_47">specific chemotherapy agent, dose, and schedule of administration. Systemic therapy/RT should be </span>
<span id="t2u_47" class="t s8_47">performed by an experienced team and should include substantial supportive care. </span>
<span id="t2v_47" class="t se_47">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
